TELA Bio to Participate in Upcoming Canaccord Genuity Musculoskeletal Conference in Chicago, IL

MALVERN, Pa., March 16, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the Canaccord Geunity Musculoskeletal Conference on March 22, 2022 in Chicago, IL.

TELA Bio’s management is scheduled to present at the 2022 Canaccord Genuity Musculoskeletal Conference on Tuesday, March 22, 2022 at 3:30pm CT.  Interested parties can access the live and archived webcast at ir.telabio.com.

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Investor Contact
Greg Chodaczek
332-895-3230
ir@telabio.com